- Report
- May 2020
- 205 Pages
Global
From €3277EUR$3,600USD£2,783GBP
- Report
- March 2024
- 322 Pages
United States
From €7277EUR$7,995USD£6,181GBP
- Report
- March 2023
- 112 Pages
Global
From €4546EUR$4,995USD£3,861GBP
- Report
- March 2023
- 648 Pages
Global
From €9097EUR$9,995USD£7,727GBP
- Report
- April 2022
- 93 Pages
Global
From €3500EUR$4,119USD£3,077GBP
- Report
- August 2023
- 226 Pages
Global
From €2275EUR$2,499USD£1,932GBP
€3249EUR$3,570USD£2,760GBP
- Report
- March 2022
- 220 Pages
Global
From €2202EUR$2,419USD£1,870GBP
€3146EUR$3,456USD£2,672GBP
Sacral nerve stimulation (SNS) is a type of neuromodulation therapy used to treat a variety of neurological conditions. It involves the implantation of a small device that sends electrical signals to the sacral nerve, which is located near the tailbone. The device is used to reduce symptoms such as urinary and fecal incontinence, chronic pelvic pain, and overactive bladder. It is also used to treat certain types of constipation.
SNS is a minimally invasive procedure that is typically performed in an outpatient setting. It is considered a safe and effective treatment option for many patients. The device is programmed to deliver electrical signals to the sacral nerve, which can help reduce symptoms and improve quality of life.
The SNS market is a growing segment of the neurology devices industry. It is expected to continue to grow as more patients seek out this treatment option. Companies in the SNS market include Medtronic, Boston Scientific, St. Jude Medical, and Nevro. Show Less Read more